

Haller J Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6596414/publications.pdf>

Version: 2024-02-01

21
papers

387
citations

840776

11
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

617
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2015, 139, 59-62.	1.4	45
2	Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. <i>Gynecologic Oncology Reports</i> , 2017, 20, 81-86.	0.6	44
3	Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. <i>Molecular Cancer Research</i> , 2018, 16, 813-824.	3.4	42
4	Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy. <i>Gynecologic Oncology</i> , 2018, 151, 282-286.	1.4	42
5	Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. <i>Oncotarget</i> , 2017, 8, 44159-44170.	1.8	41
6	The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis. <i>Gynecologic Oncology</i> , 2017, 146, 642-646.	1.4	31
7	Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2019, 153, 381-384.	1.4	28
8	The antitumor effects of entinostat in ovarian cancer require adaptive immunity. <i>Cancer</i> , 2018, 124, 4657-4666.	4.1	22
9	The financial impact of an enhanced recovery after surgery (ERAS) protocol in an academic gynecologic oncology practice. <i>Gynecologic Oncology</i> , 2020, 156, 284-287.	1.4	17
10	Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 709-717.	2.8	14
11	Does health literacy impact technological comfort in cancer patients?. <i>American Journal of Surgery</i> , 2022, 223, 722-728.	1.8	12
12	Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm. <i>Gynecologic Oncology</i> , 2020, 159, 773-777.	1.4	11
13	See-and-Treat for High-Grade Cytology: Do Young Women Have Different Rates of High-Grade Histology?. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 243-246.	1.9	10
14	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1569-1575.	2.5	10
15	Enhanced Recovery After Surgery in Surgical Specialties. <i>Surgical Clinics of North America</i> , 2018, 98, 1275-1285.	1.5	5
16	Implementation and evaluation of a novel subspecialty society fellows robotic surgical course: the SGO minimally invasive academy surgical curriculum. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e26.	2.2	4
17	Malignant Brenner tumor associated with a germline BRCA2 mutation. <i>Gynecologic Oncology Reports</i> , 2017, 21, 17-19.	0.6	3
18	Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting. <i>Gynecologic Oncology Reports</i> , 2019, 29, 123-125.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service. <i>Gynecologic Oncology</i> , 2016, 143, 105-108.	1.4	2
20	An enhanced recovery protocol decreases complication rates in high-risk gynecologic oncology patients undergoing non-emergent laparotomy. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 721-726.	2.5	1
21	Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman. <i>Gynecologic Oncology</i> , 2018, 151, 6-9.	1.4	0